A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice

← catalyst calendar

NCT05637112 · readout in 1,594 d

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.

Phase

—

Status

Active, not recruiting

Study type

Observational

Enrollment

551actual

Sites

Countries

Austria, Belgium, Canada +6

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-02-27

actual

When the study began enrolling

Primary completion

2030-12-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2030-12-30

estimated

The whole study's end, after follow-up

First posted

2022-12-05

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-26

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Systemic Lupus Erythematosus

Intervention

Other: None (Observational study) — also filed as Observational Study

Primary outcomes

what the primary-completion date above is the date OF

Disease activity assessed by the Physician Global Assessment (PGA)

measured From Baseline (1 year pre-anifrolumab) until follow-up 5 years post-anifrolumab initiation

Disease activity assessed by Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)

measured From Baseline (1 year pre-anifrolumab) until follow-up 5 years post-anifrolumab initiation

Proportion of patients attaining the composite endpoint of lupus low disease activity (LLDAS)

measured From Baseline (1 year pre-anifrolumab) until follow-up 5 years post-anifrolumab initiation

Publications

PMID 39578022 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed